Fosbretabulin (disodium)

Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis[1][3].

Product Specifications

CAS Number

[168555-66-6]

Product Name Alternative

CA 4DP; CA 4P; Combretastatin A4 disodium phosphate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Microtubule/Tubulin

Type

Natural Products

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fosbretabulin-disodium.html

Purity

99.91

Solubility

DMF : < 1 mg/mL|H2O : 4.5 mg/mL (ultrasonic; warming)

Smiles

COC1=C(OC)C(OC)=CC(/C=C\C2=CC=C(OC)C(OP(O[Na])(O[Na])=O)=C2)=C1

Molecular Formula

C18H19Na2O8P

Molecular Weight

440.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Shen CH, et, al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol. 2010 Aug;160 (8) :2008-27.|[2]Pettit GR, et, al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z) - and (E) -combretastatin A-41. J Med Chem. 2005 Jun 16;48 (12) :4087-99.|[3]Tozer GM, et, al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999 Apr 1;59 (7) :1626-34.